Alta Sciences

AUGUST 29, 2024

billion USD by 2028. Large molecules are less able to penetrate the blood/brain barrier to deliver therapeutic results and thus most CNS-active drugs are small molecules.” --The Altascientist, Issue 33, pg. billion USD in 2023 to $166.53

Drug Development 52

Drug Development Clinical Trials Small Molecule Drugs 52

The Pharma Data

NOVEMBER 8, 2020

All Almirall’s production sites continue to operate at full capacity in order to be able to ensure the supply of medicines to all patients requiring treatment. Tirbanibulin is a topical drug for the treatment of actinic keratosis in adult patients developed by Athenex and licensed by Almirall.

Licensing 52

Licensing Licensing Marketing Production 52

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. The prophylactic steroid treatment was also changed from 1 mg/kg to an intermediate dose of 2mg/kg. The most frequent treatment-emergent adverse events were nasopharyngitis and atopic dermatitis.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52